Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital - Takeaways - MDSpire

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

  • By

  • Olga Rogozina

  • Susana Martín-López

  • Fiorela Cinthia Dueñas López

  • Zoraida del Solar Moreno

  • Larry Leiva Castrejon

  • Daniela Aguilar-Concepción

  • María Jiménez-González

  • Ana Martínez Feito

  • Miguel González-Muñoz

  • Elena Ramírez

  • May 15, 2026

  • 0 min

Share

  • 1

    The study evaluated lymphocyte transformation testing (LTT) for diagnosing drug hypersensitivity in pediatric patients.

  • 2

    LTT demonstrated 100% sensitivity and negative predictive value, indicating its reliability in identifying culprit drugs.

  • 3

    The most common adverse drug reactions were cutaneous and hepatic, with amoxicillin and paracetamol being frequent culprits.

  • 4

    LTT positivity significantly correlated with high causality scores and drug provocation testing outcomes.

  • 5

    LTT is a valuable, non-invasive tool for assessing T-cell mediated reactions, especially when drug provocation testing is risky.

Original Source(s)

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital

  • by Olga Rogozina, Susana Martín-López, Fiorela Cinthia Dueñas López, Zoraida del Solar Moreno, Larry Leiva Castrejon, Daniela Aguilar-Concepción, María Jiménez-González, Ana Martínez Feito, Miguel González-Muñoz, Elena Ramírez

  • May 15, 2026

Related Content

FDA OKs Linaclotide in Young Children

Phase 3 data expanded use of linaclotide 72 mcg in pediatric functional constipation.

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.